Annals of Hematology

, Volume 98, Issue 11, pp 2625–2626 | Cite as

Reversal of skin changes in smoldering myeloma with clinical presentation of POEMS syndrome with a lenalidomide-based regimen

  • Elena E SolomouEmail author
  • Panayiotis Marnellos
  • Agathoclis Agathokleous
  • Georgia Kyriakou
  • Sophia Georgiou
  • Argiris Symeonidis
Letter to the Editor

Dear editor,

POEMS (Takatsuki or Crow-Fukase syndrome), the acronym for polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes, is a rare multi systemic disorder [1]. It affects men more often than women and usually presents in the 6th decade of life. Skin changes are prominent, with hyperpigmentation being the most frequent alteration [2]. Sclerodermoid skin changes are also very common, and white nails (leukonychia) are characteristic of the disease. Cutaneous angiomas can be present as well as vasculitis, hypertrichosis, and acrocyanosis. Hepatomegaly, splenomegaly, and/or enlarged lymph nodes can also be seen. Hypothyroidism, adrenal insufficiency, and diabetes mellitus represent the most common endocrine system–related disorders. Usually a monoclonal band is seen in serum protein electrophoresis; however, the number of plasma cells that infiltrate the bone marrow can be only slightly elevated. The rarity of the disease delays the diagnosis [3].



Compliance with ethical standards

All procedures performed in this manuscript were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from the individual participant described herein to be included in this study.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Nozza A (2017) POEMS syndrome: an update. Mediterr J Hematol Infect Dis 9(1):e2017051CrossRefGoogle Scholar
  2. 2.
    Dispenzieri A (2015) POEMS syndrome: update on diagnosis, risk-stratification, and management. Am J Hematol 90:951–962CrossRefGoogle Scholar
  3. 3.
    Suichi T, Misawa S, Sato Y et al (2019) Proposal of new clinical diagnostic criteria for POEMS syndrome. J Neurol Neurosurg Psychiatry 90:133–137CrossRefGoogle Scholar
  4. 4.
    Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E (2017) Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol 179:748–755CrossRefGoogle Scholar
  5. 5.
    Dispenzieri A (2012) How I treat POEMS syndrome. Blood 119:5650–5658CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal Medicine, Patras University HospitalUniversity of Patras Medical SchoolPatrasGreece
  2. 2.American Medical CenterNicosiaCyprus
  3. 3.Bank of Cyprus Oncology CenterNicosiaCyprus
  4. 4.Department of DermatologyUniversity of Patras Medical SchoolRionGreece
  5. 5.Department of HematologyUniversity of Patras Medical SchoolRionGreece

Personalised recommendations